The pathological aggregation of amyloid-beta peptides (Aβ) is one of the major causes for the progressive cognitive decline in AD patients. The development of compounds interfering with Aβ aggregation and thus able to rescue neurodegeneration is indispensible. For this purpose, fast and reliable assays are needed capable of showing direct effects of compounds on Aβ oligomer formation.
QPS Neuropharmacology provides exclusively a fast and reproducible screening assay, Amorfix Aggregated Aβ Assay (A4), able to directly visualize beneficial effects of your developmental compounds on the formation of Aβ aggregates in vitro. Notably, compound Y and Z were able to reduce Aβ aggregate formation as determined by A4 assay.
Figure: Determination of Aβ oligomers in vitro by A4 Assay. Compounds were co-aggregated with Aβ1-42 for 48h in vitro. Aggregated Aβ was separated from monomers through affinity interaction. After disaggregation, the originally aggregated Aβ was detected using a bead-based immunoassay that applies human Aβ-specific antibody labeled beads and Time Resolved Fluorescence (TRF) measurements. Aβ levels were evaluated as signal to noise ratio (S/N). Co-aggregation of compound Y and Z as well as reference item (RI) with Aβ1-42 reduced aggregate formation.